الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastiska medel - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - kolorektala neoplasmer - antineoplastic agents, protein kinase inhibitors - stivarga är indicerat som monoterapi för behandling av vuxna patienter med metastaserad kolorektal cancer (crc) som har varit tidigare har behandlats med, eller inte anses vara kandidater för, tillgängliga behandlingar - dessa inkluderar fluoropyrimidine-baserad kemoterapi, en anti-vegf-behandling och en anti-egfr-behandling, unresectable eller metastaserande gastrointestinala stromala tumörer (gist) som kommit på eller är intoleranta mot tidigare behandling med imatinib och sunitinib, hepatocellulär cancer (hcc) som har varit tidigare har behandlats med sorafenib.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - prostatiska neoplasmer - terapeutiska radioaktiva läkemedel - xofigo är indicerat för behandling av vuxna med castreringsresistent prostatacancer, symtomatiska benmetastaser och inga kända viscerala metastaser.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

viatris limited - tadalafil - hypertoni, lungformig - urologiska - talmanco är indicerat hos vuxna för behandling av pulmonell arteriell hypertension (pah) klassificerad som who-funktionsklass ii och iii, för att förbättra träningskapaciteten. effekt har visats i idiopatisk pah (ipah) och i pah relaterat till kollagenvaskulär sjukdom.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

virbac s.a. - rekombinant omega-interferon av felint ursprung - immunstimulatorer, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. hos katter infekterade av fiv var mortaliteten låg (5%) och påverkades inte av behandlingen.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - läkemedel mot obstruktiv lungsjukdom, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - läkemedel mot obstruktiv lungsjukdom, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - läkemedel mot obstruktiv lungsjukdom, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.